Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AB-836 in Healthy Subjects and Chronic Hepatitis B
NCT04775797Phase 1Terminated
- Sponsor
- Arbutus Biopharma Corporation
- Start
- Jun 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, randomised, double-blind trial of AB-836 in Chronic Hepatitis B (CHB) (5 arms), sponsored by Arbutus Biopharma Corporation. Primary endpoints: Incidence of Treatment-Emergent Adverse Events, Incidence of discontinuations due to Adverse Events and 2 more. Started Jun 2021; status: terminated.
02
Drugs
AB-836
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04775797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04775797.